Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2024-01-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about receiving approval from the National Medical Products Administration (国家药监局) to conduct clinical trials for a new drug. It details the drug's basic information, development status, and risk warnings. There are no financial statements, earnings data, or management discussions typical of financial reports. The document is a regulatory announcement about a clinical trial approval, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-01-18 Chinese
天士力2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2024 First Extraordinary General Meeting" of the company TianShiLi Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on various proposals, and legal witness statements. The content focuses on the official announcement of voting results from a shareholders' meeting, including approval of proposals and legal validation. There is no indication of a full annual or interim report, financial statements, or management discussion. The document is not a proxy solicitation or a presentation but an official announcement of voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 2564 characters, which is consistent with an announcement rather than a full report. Confidence is high due to clear voting results and meeting details provided.
2024-01-03 Chinese
天士力关于为子公司提供担保的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of guarantees provided by the company to its subsidiary. It details the guarantee amount, the internal decision-making process, the necessity and reasonableness of the guarantee, and cumulative guarantee amounts. It does not contain financial statements or detailed financial performance data. The document is relatively short (2587 characters) and serves as a regulatory announcement about a specific corporate action (providing guarantees to a subsidiary). It fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-03 Chinese
内蒙古建中律师事务所关于天士力医药集团股份有限公司2024年第一次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures, attendance, and voting results of a company's 2024 first extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or performance data but focuses on the legal compliance of the shareholders' meeting process. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, not an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Legal Proceedings Report (LTR). The document length is 2460 characters, which is consistent with a detailed legal opinion letter rather than a brief announcement or a full financial report.
2024-01-03 Chinese
天士力关于减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from the company TianShiLi Pharmaceutical Group Co., Ltd. regarding a reduction in registered capital and notification to creditors. It details the background of share repurchases, the decision to cancel shares to reduce registered capital, and the legal rights of creditors to claim debts or request guarantees within 45 days. The document includes contact information for creditors to make claims. It is not a financial report, earnings release, or management discussion, but a formal regulatory announcement about capital changes and creditor notification. The document length is short (1407 characters) and it is a standalone announcement, not a report or presentation. This fits the category of Share Issue/Capital Change (SHA) as it concerns changes in registered capital due to share cancellation.
2024-01-03 Chinese
天士力关于终止出售控股子公司股权的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of TianShiLi Pharmaceutical Group Co., Ltd. regarding the termination of a planned sale of controlling shares in subsidiaries. It details the board meeting resolutions, the background of the transaction, the reasons for termination, and the impact on the company. There are no financial statements or detailed financial data presented. The document is a formal announcement about a corporate transaction decision rather than a full report or detailed financial disclosure. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate event that does not fit into more specific categories like M&A Activity or Capital/Financing Update because it announces termination rather than a new transaction or financing event.
2023-12-29 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.